SCHEMBL105022

SCHEMBL105022

CC(C)CCc1ccc(CC(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
HPGD P15428 1/20 0.58
HSD17B10 Q99714 1/20 0.58
CA2 P00918 1/20 0.52
CAMK2A Q9UQM7 1/20 0.52
AKR1B1 P15121 1/20 0.50
ABCC4 O15439 1/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 1/20 0.48
PTGS1 P23219 1/20 0.48
HTT P42858 1/20 0.48
KLKB1 P03952 1/20 0.46
CTSB P07858 1/20 0.46
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
ANPEP P15144 1/20 0.44
ENPEP Q07075 1/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104462 0.84 FFAR1 (0.59) ALDH1A1CA2LMNATHRATHRB
SCHEMBL11578170 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL10087025 0.82 AKR1B1 (0.48) HPGDHSD17B10AKR1B1LMNAGAA
SCHEMBL11376653 0.82 AKR1B1 (0.58) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL2996429 0.80 CA2 (0.68) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL15374641 0.80 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10TSHRHTT
SCHEMBL104594 0.80 GRIN2D (0.57) ALDH1A1GAATSHRHTTTHRB
SCHEMBL8080450 0.80 HTT (0.41) TSHRHTT
SCHEMBL406107 0.79 MAPT (0.59) ALDH1A1HSD17B10LMNAFFAR1
Bicarbonate SCHEMBL27892668 0.79 TSHR (0.59) ALDH1A1HPGDLMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 US disclosed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 WO disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
EP-0977989-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2000-02-09 EP disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998007671-A1 SEPARATING ENANTIOMERS BY MOLECULAR IMPRINTING IGEN, INC. (US) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 ALDH1A1 3128/4885HPGD 4110/4885HSD17B10 1704/4885
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 ALDH1A1 1713/4885HPGD 664/4885HSD17B10 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.